Back to Search Start Over

A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products.

Authors :
Atanackovic D
Iraguha T
Omili D
Avila SV
Fan X
Kocoglu M
Gebru E
Baker JM
Dishanthan N
Dietze KA
Oluwafemi A
Hardy NM
Yared JA
Hankey K
Dahiya S
Rapoport AP
Luetkens T
Source :
Cytotherapy [Cytotherapy] 2024 Apr; Vol. 26 (4), pp. 318-324. Date of Electronic Publication: 2024 Feb 10.
Publication Year :
2024

Abstract

Background Aims: Chimeric antigen receptor (CAR) T-cell (CAR-T) therapies have revolutionized the treatment of B-cell lymphomas. Unfortunately, relapses after CD19-targeted CAR-T are relatively common and, therefore, there is a critical need for assays able to assess the function and potency of CAR-T products pre-infusion, which will hopefully help to optimize CAR-T therapies. We developed a novel multicolor fluorescent spot assay (MFSA) for the functional assessment of CAR-T products on a single-cell level, combining the numerical assessment of CAR-T products with their functional characterization.<br />Methods: We first used a standard single-cell interferon (IFN)-γ enzyme-linked immune absorbent spot assay to measure CD19-targeted CAR-T responses to CD19-coated beads. We then developed, optimized and validated an MFSA that simultaneously measures the secretion of combinations of different cytokines on a single CAR-T level.<br />Results: We identified IFN-γ/tumor necrosis factor-α/granzyme B as the most relevant cytokine combination, and we used our novel MFSA to functionally and numerically characterize two clinical-grade CAR-T products.<br />Conclusions: In conclusion, we have developed a novel assay for the quantitative and functional potency assessment of CAR-T products. Our optimized MFSA is cost-effective, easy to perform, reliable, can be performed overnight, allowing for a fast delivery of the product to the patient, and requires relatively minimal maintenance and training. The clinical value of our novel assay will be assessed in studies correlating the pre-infusion assessment of CAR-T products with the patients' outcome in a prospective fashion.<br />Competing Interests: Declaration of Competing Interest SD serves on advisory boards for Bristol-Myers Squibb, Incyte and Atara Biotherapeutics. The remaining authors declare that they do not have any competing interests.<br /> (Copyright © 2024 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1477-2566
Volume :
26
Issue :
4
Database :
MEDLINE
Journal :
Cytotherapy
Publication Type :
Academic Journal
Accession number :
38340107
Full Text :
https://doi.org/10.1016/j.jcyt.2024.01.006